Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To analyse the correspondence between aMMP-8 PoC test results and the clinical endpoints of non-surgical periodontal treatment in stage III/IV periodontitis.
Background: The diagnostic success of the active-matrix metalloproteinase-8 (aMMP-8) point-of-care (PoC) test has been demonstrated in various studies, but the evidence of its accuracy following periodontal treatment is limited.
Materials And Methods: Altogether 42 stage III/IV grade C periodontitis patients were included in this prospective diagnostic study. Clinical periodontal indices were recorded, aMMP-8 PoC test was applied and mouthrinse was collected before and at 6, 12 and 24 weeks after non-surgical periodontal treatment. Quantitative aMMP-8 levels were determined with immunofluorometric assay (IFMA) for the verification of the PoC test results. The accuracy of the aMMP-8 PoC test was assessed using previously established clinical endpoints as references.
Results: Sensitivity and specificity of aMMP-8 PoC test to indicate clinical endpoints were ranged as follows: Sensitivity 71.4% at baseline, 39.3%-42.4% at week 6, 28.6%-32.4% at week 12 and 35.3%-42.9% at week 24; specificity 64.3%-80% at week 6, 40%-57.1% at week 12 and 56%-64.3% at week 24.
Conclusions: The accuracy of aMMP-8 PoC test in identifying clinical endpoints after non-surgical periodontal treatment is reduced in relation to baseline. Individual healing patterns of each diseased pocket eventually limit the accuracy of the dichotomous aMMP-8 oral rinse test during the post-treatment period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jre.13093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-phosphorylating DNAzyme DK1 enables programmable multi-analyte readout via PfAgo.
Biosens Bioelectron
September 2025
Department of Biological Sciences, Faculty of Science, National University of Singapore, 117543, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Precision Medicine Translational Research Programme (TRP), Yong Loo Lin School
DNAzymes possessing kinase-like activities have long held theoretical promise, yet their practical implementation has remained significantly limited. Notably, DNAzyme kinase 1 (DK1), discovered over two decades ago, exhibits a unique self-phosphorylation capability upon encountering specific substrates like ATP, but its broad-based and programmable applications have not yet been fully realized. In this study, we innovatively couple DK1's autophosphorylation mechanism with the PfAgo to establish a novel programmable cascade sensing platform named RASTEN (Robust pfAgo-based Strategy for POC Testing Non-nucleic Acid and Nucleic Acid).
View Article and Find Full Text PDFDiagnostic and analytic performance of four point-of-care hemoglobin testing devices used in routine HIV and maternity care in Uganda.
BMC Health Serv Res
September 2025
Rakai Health Sciences Program, P.O. Box 279, Kalisizo, Uganda.
Background: Hemoglobin estimation (Hb) is the most requested hematology test, especially among pregnant/postnatal women and people living with HIV (PLHIV). In Uganda, several point-of-care (POC) Hb testing devices are currently used and performance may be affected by multiple factors. This study evaluated the diagnostic and analytic performance of four Hb POC devices.
View Article and Find Full Text PDFFacilitating Earlier Diagnosis of Pulmonary Hypertension Using a Novel Noninvasive Diagnostic.
JACC Case Rep
September 2025
Atrium Health Navicent, Macon, Georgia, USA.
Background: Pulmonary hypertension (PH) is frequently underdiagnosed due to limitations of transthoracic echocardiography, particularly when tricuspid regurgitant velocity (TRV) is unmeasurable. CorVista PH (point-of-care test for pulmonary hypertension [POC-PH]) is a novel, Food and Drug Administration-cleared point-of-care diagnostic with 82% sensitivity and 92% specificity for identifying mean pulmonary artery pressure elevation.
Summary: We present a patient who underwent multiple transthoracic echocardiograms negative for PH.
Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to Antidepressants: A Phase 2 Randomized, Placebo-Controlled, Parallel Group, Dose-Ranging Trial.
J Clin Psychiatry
September 2025
Therapeutic Area Mental Health, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany.
To assess proof-of-concept (PoC) for efficacy, tolerability, and safety of TRPC4/5 inhibitor BI 1358894 vs placebo in patients with major depressive disorder (MDD) with inadequate response to ongoing antidepressants. In this phase 2, multicenter, randomized, double-blind, dose-finding trial (December 2020-February 2024), patients with MDD (per ) and current depressive episode of ≥8 weeks and ≤24 months were randomized (3.5:1:1:1:2:2) to receive placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) or quetiapine 150-300 mg orally, once daily for 6 weeks.
View Article and Find Full Text PDFManaging Cognitive Decline Through a Social Robot-Based Intervention: Protocol for the engAGE Proof of Concept and Randomized Controlled Trial.
JMIR Res Protoc
September 2025
Scientific Direction, Istituto Nazionale di Riposo e Cura per Anziani, Ancona, Italy.
Background: Dementia is challenging society in terms of the quality of life, the costs of health care systems, and caregivers' burden. Dementia is often preceded by a status of mild cognitive impairment (MCI), during which a healthy lifestyle and cognitive therapy seem to be effective in counteracting the decline.
Objective: The engAGE (Managing Cognitive Decline Through Theatre Therapy, Artificial Intelligence, and Social Robot-Driven Interventions) project aimed to build a technological platform to counteract cognitive decline in older adults with MCI through both cognitive therapy and lifestyle management.